Rally to raise awareness against drug usage held
Pic: JITO Belgaum, in association with the FDA, organised a rally to raise awareness for the International Day Against Drug Abuse and Illicit Trafficking on Thursday.
Belagavi: The Jain International Trade Organisation (JITO) Belagavi, in association with the Food Safety & Drug Administration (FDA), Belagavi, successfully organised a rally to raise awareness as part of the International Day Against Drug Abuse and Illicit Trafficking on Thursday.
The event saw an impressive gathering of over 1,000 students, the public, and other participants at Rani Channamma Circle, Belagavi. The rally was flagged off by chief guest Bhushan Gulabrao Borase, commissioner of police, Belagavi City, from Rani Channamma Circle. He participated in the rally until its conclusion at the KLE Centenary Convention Center and addressed the gathering with a few inspiring words. JITO Belagavi chairman Harshavardhan Inchal accompanied the rally.
Deputy drug controller Nagaraj, assistant drug controllers K Mallikarjun, Raghuram N, Manohar, drug inspector Renuprasad, and Dayanand from the Food Safety and Drug Administration (FDA), Belagavi, were present. From JITO Belagavi, event convenor and physician Dr Devagouda Imagoudanavar, along with many other JITO members, were also present.
This mega-rally garnered significant support from the Belgaum District Retailer and Wholesale Pharma Association, as well as various educational institutions such as KLE University, Rani Chennamma College of Pharmacy, Maratha Mandal College of Pharmacy, Sagar College of Pharmacy, Shree Paramedical, Bharatesh Nursing College, and many more organisations.
Throughout the rally, participants enthusiastically chanted slogans to amplify awareness. At the conclusion of the event, JITO Belagavi chief secretary Abhay Adimani extended his gratitude to all who were present, acknowledging their contributions in making the rally a grand success.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
26 minutes ago
- Time of India
International Day Against Drug Abuse and Illicit Trafficking: Awareness events against drug abuse held across city
Kochi: At a time when society has grown increasingly vigilant about drug menace following a series of violent crimes, International Day Against Drug Abuse and Illicit Trafficking was observed in city with renewed calls for awareness, stronger enforcement and community-based prevention efforts. Commissionerate of customs (preventive), Kochi, conducted an awareness campaign for schoolchildren as part of Mission Drug Free India at Ernakulam Govt Higher Secondary School for Girls. Chief commissioner, central tax, central excise and customs, Shaikh Khader Rahaman inaugurated the function. Commissioner T Tiju conducted awareness session for students. Infopark hosted a range of programmes featuring a rally by students from eight schools. Adding a unique touch to the event, Thrikkakara assistant commissioner of police Shiju P S performed a song during inaugural ceremony at Athulya auditorium, helping draw more attention to the cause. Addressing the gathering, Shiju called upon children to earn the courage and determination to say 'no' even to close friends who may encourage them to do wrong things. Anti-drug rally was taken out from Athulya building to Infopark police station. Infopark assistant manager Sajith N G administered anti-drug pledge at the conclusion of the rally, which was organized by Infopark police station along with Progressive Techies — a socio-cultural and welfare organization of IT employees. At Park Centre, which is the administrative hub of IT complex in suburban Kakkanad, employees took an anti-drug pledge in the presence of Infopark CEO Susanth Kurunthil. Actor Prithviraj Sukumaran inaugurated an anti-drug campaign titled No Entry as part of the launch of a five-year project, SAFE (Substance Abuse Free Environment Village), being implemented in Ernakulam parliamentary constituency under the leadership of Hibi Eden, MP. Eden said goal of the project is to ensure collaborative efforts of public representatives, educational institutions and social organizations to address the serious challenge of protecting children and youth from influence of intoxicants. Prithviraj said there is a misconception in society that drugs are a fuel for creativity in film industry. He stated that no great work was ever created under influence of any drug. A drug awareness seminar was organized at Edathala MES MK Mackar Pillai College for Advanced Studies under the leadership of rural district police. An awareness cycle rally was conducted under the guidance of Kodanad police station. Perumbavoor ASP Shakti Singh Arya inaugurated the event. A pledge against drugs was taken at rural district police headquarters and additional SP M Krishnan administered oath.
Economic Times
2 hours ago
- Economic Times
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
What's Behind the FDA's New Warning? Who Faces the Highest Risk? Live Events What's Changing in the Vaccine Labels? What's the FDA Doing Next? FAQs (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update:"Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
Time of India
3 hours ago
- Time of India
FDA issues new heart risk warnings for Pfizer, Moderna COVID vaccines - should you be worried?
The US Food and Drug Administration (FDA) has warned that COVID-19 vaccines, which are manufactured by Pfizer and Moderna, have the potential for cardiac risks, as per a report. What's Behind the FDA's New Warning? These warnings were first proposed in letters, which were sent to both companies in April, providing additional information about the potential risks of myocarditis and/or pericarditis associated with the two vaccines, as reported by the Cardiovascular Business report. Myocarditis and pericarditis have the possibility of leading to long-term heart damage, according to the report. ALSO READ: Meet Trapit Bansal, Meta's new AI superintelligence team hire - Is Meta poaching top talent from OpenAI? by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Who Faces the Highest Risk? FDA's latest update covers Pfizer's Comirnaty vaccine and Moderna's Spikevax vaccine, while both companies had mentioned text about myocarditis and pericarditis in the labelling for these vaccines since 2021, but the FDA wanted more information added to these warnings that specifically mentions the increased risks for young men, as per the Cardiovascular Business report. ALSO READ: After Canada, now US: College graduates face the toughest job market in decades – what's gone wrong? Live Events What's Changing in the Vaccine Labels? According to the Cardiovascular Business report, the new labeling for both the vaccines is now required to include the following text, as per FDA's latest update: "Based on analyses of commercial health insurance claims data from inpatient and outpatient settings, the estimated unadjusted incidence of myocarditis and/or pericarditis during the period 1 through 7 days following administration of the 2023-2024 Formula of mRNA COVID-19 vaccines was approximately 8 cases per million doses in individuals 6 months through 64 years of age and approximately 27 cases per million doses in males 12 through 24 years of age," as quoted in the report. The label should also include, "Follow-up information on cardiovascular outcomes in hospitalized patients who had been diagnosed with COVID-19 vaccine-associated myocarditis is available from a longitudinal retrospective observational study. Most of these patients had received a two-dose primary series of an mRNA COVID-19 vaccine prior to their diagnosis. In this study, at a median follow-up of approximately 5 months post-vaccination, persistence of abnormal cardiac magnetic resonance imaging (CMR) findings that are a marker for myocardial injury was common. The clinical and prognostic significance of these CMR findings is not known," as quoted by the Cardiovascular Business report. ALSO READ: Top economist warns: US faces a crisis worse than recession — here's what could be coming What's the FDA Doing Next? While, FDA has also emphasised that it plans to keep tracking the safety of COVID-19 vaccines from now on, as per the report. The agency said, 'Continuous monitoring and assessment of the safety of all vaccines, including the mRNA COVID-19 vaccines, is an FDA priority and we remain committed to informing the public when we learn new information about these vaccines,' adding, 'In addition, as part of the approvals of Comirnaty and Spikevax, each manufacturer is required by FDA to conduct a study to assess if there are long-term heart effects in people who have had myocarditis after receiving an mRNA COVID-19 vaccine. These studies are underway,' quoted by the Cardiovascular Business report. FAQs Why is the FDA updating warnings now? The FDA wants the public to have clearer information about rare heart-related risks linked to COVID-19 mRNA vaccines, especially for young men, as per the Cardiovascular Business report. Are Moderna and Pfizer vaccines still considered safe? Yes, the FDA continues to support their use, but these warnings are about rare side effects, as per the Cardiovascular Business report.
